OHSU Knight Cancer Institute
Enasidenib(OHSU Knight Cancer Institute)은 Acute Myeloid Leukemia 표적 ADC로, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: targeting altered metabolic pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 73.5% (ClinicalTrials.gov NCT02677922). PK: t½ 7.9 h. 차별점: novel approaches have emerged, such as covalent inhibitors like LY3410738, which irreversibly bind mutant residues, and dual.
Acute Myeloid Leukemia
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8
Discontinued
CAR T cell function by restraining antioxidant metabolism an
novel approaches have emerged, such as covalent inhibitors like LY3410738, which irreversibly bind mutant residues, and dual
targeting altered metabolic pathway
apoptosis, and emerging Menin inhibitors for specific subtypes like KMT2A-rearranged or NPM1-mutant AML
biomarkers to achieve cures beyond APL
resistance mechanisms and inform therapeutic strategies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
OHSU Knight Cancer Institute
Enasidenib(OHSU Knight Cancer Institute)은 Acute Myeloid Leukemia 표적 ADC로, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: targeting altered metabolic pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 73.5% (ClinicalTrials.gov NCT02677922). PK: t½ 7.9 h. 차별점: novel approaches have emerged, such as covalent inhibitors like LY3410738, which irreversibly bind mutant residues, and dual.
Acute Myeloid Leukemia
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8
Discontinued
CAR T cell function by restraining antioxidant metabolism an
novel approaches have emerged, such as covalent inhibitors like LY3410738, which irreversibly bind mutant residues, and dual
targeting altered metabolic pathway
apoptosis, and emerging Menin inhibitors for specific subtypes like KMT2A-rearranged or NPM1-mutant AML
biomarkers to achieve cures beyond APL
resistance mechanisms and inform therapeutic strategies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.